Core Points - Transgene has requested the suspension of trading of its shares on Euronext Paris pending the publication of the results of its capital increase, with trading set to resume on 27 November 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [2] - The company's lead asset is TG4050, an individualized therapeutic vaccine based on the myvac® platform, which has shown proof of principle in treating head and neck cancers [2] - Transgene is also developing other viral vector-based assets, including BT-001, an oncolytic virus in clinical development, and is engaged in innovative discovery and preclinical work for novel viral vector-based modalities [2] Technology and Innovation - The myvac® platform allows for the creation of personalized virus-based immunotherapies that encode patient-specific mutations identified through advanced AI technologies [3] - Transgene's proprietary Invir.IO® platform is aimed at designing a new generation of multifunctional oncolytic viruses, leveraging the company's expertise in viral vector engineering [4]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares, targeting specialized investors via private placement and retail investors through the PrimaryBid platform [2][6] - The company aims to accelerate the development of its myvac® platform, particularly the individualized cancer vaccine TG4050, which has shown promising results in patients with operable head and neck cancer [4][5] - The funds raised will extend the company's financial visibility until early 2028, allowing for ongoing clinical trials and preparation for potential pivotal trials [6][8] Fundraising Details - The fundraising consists of a private placement for institutional investors and a public offering for retail investors, with TSGH committing to invest at least €70 million [11][14] - The private placement and PrimaryBid offering will close on November 26, 2025, with trading of Transgene shares suspended on that day [6][32] - The net proceeds from the fundraising will be allocated primarily to the myvac® program (approximately 70%), followed by R&D costs (approximately 20%), and general operational expenses [7][8] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on its Current Account Advance [9] - Following the fundraising, the company expects to meet its working capital requirements until early 2028, significantly improving its financial stability [10][8] - The Reserved Capital Increase of approximately €39.4 million will be executed at the same price as the private placement, converting debt into equity and strengthening the company's balance sheet [34][36] Expected Milestones - Key milestones for the myvac® platform include follow-up data from ongoing trials in head and neck cancers, with significant data expected in 2026 and 2027 [13] - The company plans to launch a Phase 1 trial in a new indication once financing conditions are met, with preparations for late-stage trials expected to conclude by the end of 2027 [12][13] Shareholder Structure - As of the date of the press release, TSGH holds 68.87% of the company's share capital, and after the fundraising, its stake is expected to decrease slightly to 68.06% [28][29] - The fundraising will result in dilution for existing shareholders, with the shareholding percentage for a shareholder holding 1% of the capital before the fundraising expected to drop to approximately 0.63% post-issuance [27]

Core Points - Transgene has appointed Emmanuelle Quilès as an independent Director to its Board of Directors, succeeding Philippe Archinard, who is retiring [1][3] - Emmanuelle Quilès brings over 25 years of experience in strategic leadership roles within the global pharmaceutical industry, previously serving as Worldwide Vice President at Janssen Global Commercial Strategy Organization [2][5] - The appointment is effective from July 9, 2025, and Quilès will serve the remainder of Archinard's term until the 2026 Annual Shareholders' Meeting [3] Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes TG4050, TG4001, BT-001, and TG6050 [8] - The company utilizes its myvac® platform for individualized therapeutic vaccines and the Invir.IO® platform for multifunctional oncolytic viruses [9][10] - Transgene's clinical-stage programs are aimed at providing targeted immunotherapies, with a focus on precision medicine [8][9]

Core Insights - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with a particular emphasis on individualized therapies [2][3] - The company announced upcoming meetings with institutional investors and leaders in the biotechnology ecosystem to discuss its clinical data and treatment landscape for head and neck cancers [1][6] Company Overview - Transgene's lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in patients for adjuvant treatment of head and neck cancers [2] - The company also has a portfolio that includes TG4001 for HPV-positive cancers and two oncolytic viruses, BT-001 and TG6050, based on the Invir.IO® viral backbone [2] Technological Innovations - The myvac® platform allows for the creation of personalized virus-based immunotherapies tailored to individual patient mutations, utilizing AI capabilities from partner NEC [3] - Transgene is leveraging its expertise in viral vector engineering to develop a new generation of multifunctional oncolytic viruses through its proprietary Invir.IO® platform [4] Upcoming Events - Transgene will participate in several key industry events, including the BIO International Convention on June 16, 2025, in Boston, and the International Neoantigen Summit on June 24, 2025, in Amsterdam [6]

Core Viewpoint - Transgene is set to present positive clinical data for its individualized neoantigen cancer vaccine, TG4050, at the 2025 ASCO Annual Meeting, highlighting advancements in cancer immunotherapy [1][2]. Company Overview - Transgene is a biotechnology company focused on developing virus-based immunotherapies for cancer treatment, with a clinical-stage portfolio that includes TG4050, TG4001, BT-001, and TG6050 [3]. - TG4050 is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in treating head and neck cancers [3]. - The company utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its viral vector capabilities [5]. Upcoming Event - A live webcast discussing the latest findings on TG4050 will occur on June 6, 2025, featuring Transgene's management and Prof. Christian Ottensmeier, focusing on the treatment landscape for early-stage HPV-negative head and neck cancer [2].

Core Points - The Combined Ordinary and Extraordinary General Meeting of Transgene's shareholders took place on May 15, 2025, where various resolutions were voted on and approved [1][2] - The meeting resulted in the renewal of the terms of office for several Board Members, maintaining a diverse and independent Board composition [3][4] - A share capital reduction was approved, decreasing the par value of shares from €0.50 to €0.30, along with the delegation of authority for a potential reverse stock split [5] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio that includes viral vector-based immunotherapeutics [7] - The lead asset, TG4050, is an individualized therapeutic vaccine aimed at head and neck cancers, showcasing the company's innovative approach to precision medicine [8] - Transgene utilizes its proprietary Invir.IO® platform to engineer multifunctional oncolytic viruses, enhancing its capabilities in viral vector technology [9]